These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 27842383)

  • 1. Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial.
    Colombo M; Aghemo A; Liu H; Zhang J; Dvory-Sobol H; Hyland R; Yun C; Massetto B; Brainard DM; McHutchison JG; Bourlière M; Peck-Radosavljevic M; Manns M; Pol S
    Ann Intern Med; 2017 Jan; 166(2):109-117. PubMed ID: 27842383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study.
    Lawitz E; Landis CS; Flamm SL; Bonacini M; Ortiz-Lasanta G; Huang J; Zhang J; Kirby BJ; De-Oertel S; Hyland RH; Osinusi AO; Brainard DM; Robson R; Maliakkal BJ; Gordon SC; Gane EJ
    Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):918-926. PubMed ID: 32531259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
    Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
    Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
    Afdhal N; Zeuzem S; Kwo P; Chojkier M; Gitlin N; Puoti M; Romero-Gomez M; Zarski JP; Agarwal K; Buggisch P; Foster GR; Bräu N; Buti M; Jacobson IM; Subramanian GM; Ding X; Mo H; Yang JC; Pang PS; Symonds WT; McHutchison JG; Muir AJ; Mangia A; Marcellin P;
    N Engl J Med; 2014 May; 370(20):1889-98. PubMed ID: 24725239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.
    Abergel A; Asselah T; Metivier S; Kersey K; Jiang D; Mo H; Pang PS; Samuel D; Loustaud-Ratti V
    Lancet Infect Dis; 2016 Apr; 16(4):459-64. PubMed ID: 26803446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
    Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA
    Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.
    Lawitz E; Poordad FF; Pang PS; Hyland RH; Ding X; Mo H; Symonds WT; McHutchison JG; Membreno FE
    Lancet; 2014 Feb; 383(9916):515-23. PubMed ID: 24209977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
    Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X;
    Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience.
    Ueda Y; Ikegami T; Akamatsu N; Soyama A; Shinoda M; Goto R; Okajima H; Yoshizumi T; Taketomi A; Kitagawa Y; Eguchi S; Kokudo N; Uemoto S; Maehara Y
    J Gastroenterol; 2017 Aug; 52(8):986-991. PubMed ID: 28138756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
    Kowdley KV; Gordon SC; Reddy KR; Rossaro L; Bernstein DE; Lawitz E; Shiffman ML; Schiff E; Ghalib R; Ryan M; Rustgi V; Chojkier M; Herring R; Di Bisceglie AM; Pockros PJ; Subramanian GM; An D; Svarovskaia E; Hyland RH; Pang PS; Symonds WT; McHutchison JG; Muir AJ; Pound D; Fried MW;
    N Engl J Med; 2014 May; 370(20):1879-88. PubMed ID: 24720702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.
    Mizokami M; Yokosuka O; Takehara T; Sakamoto N; Korenaga M; Mochizuki H; Nakane K; Enomoto H; Ikeda F; Yanase M; Toyoda H; Genda T; Umemura T; Yatsuhashi H; Ide T; Toda N; Nirei K; Ueno Y; Nishigaki Y; Betular J; Gao B; Ishizaki A; Omote M; Mo H; Garrison K; Pang PS; Knox SJ; Symonds WT; McHutchison JG; Izumi N; Omata M
    Lancet Infect Dis; 2015 Jun; 15(6):645-53. PubMed ID: 25863559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study.
    Kohli A; Kapoor R; Sims Z; Nelson A; Sidharthan S; Lam B; Silk R; Kotb C; Gross C; Teferi G; Sugarman K; Pang PS; Osinusi A; Polis MA; Rustgi V; Masur H; Kottilil S
    Lancet Infect Dis; 2015 Sep; 15(9):1049-1054. PubMed ID: 26187031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
    Afdhal N; Reddy KR; Nelson DR; Lawitz E; Gordon SC; Schiff E; Nahass R; Ghalib R; Gitlin N; Herring R; Lalezari J; Younes ZH; Pockros PJ; Di Bisceglie AM; Arora S; Subramanian GM; Zhu Y; Dvory-Sobol H; Yang JC; Pang PS; Symonds WT; McHutchison JG; Muir AJ; Sulkowski M; Kwo P;
    N Engl J Med; 2014 Apr; 370(16):1483-93. PubMed ID: 24725238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.
    Lim JK; Liapakis AM; Shiffman ML; Lok AS; Zeuzem S; Terrault NA; Park JS; Landis CS; Hassan M; Gallant J; Kuo A; Pockros PJ; Vainorius M; Akushevich L; Michael L; Fried MW; Nelson DR; Ben-Ari Z;
    Clin Gastroenterol Hepatol; 2018 Nov; 16(11):1811-1819.e4. PubMed ID: 29306043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection.
    Gane EJ; Hyland RH; Yang Y; Svarovskaia E; Stamm LM; Brainard DM; McHutchison JG; Stedman CAM
    Gastroenterology; 2017 May; 152(6):1366-1371. PubMed ID: 28137593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.
    Feld JJ; Ramji A; Shafran SD; Willems B; Marotta P; Huchet E; Vachon ML; Svarovskaia ES; Huang KC; Hyland RH; Yun C; Massetto B; Brainard DM; McHutchison JG; Tam E; Bailey R; Cooper C; Yoshida EM; Greenbloom S; Elkhashab M; Borgia S; Swain MG
    Clin Infect Dis; 2017 Jul; 65(1):13-19. PubMed ID: 28535298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
    Charlton M; Everson GT; Flamm SL; Kumar P; Landis C; Brown RS; Fried MW; Terrault NA; O'Leary JG; Vargas HE; Kuo A; Schiff E; Sulkowski MS; Gilroy R; Watt KD; Brown K; Kwo P; Pungpapong S; Korenblat KM; Muir AJ; Teperman L; Fontana RJ; Denning J; Arterburn S; Dvory-Sobol H; Brandt-Sarif T; Pang PS; McHutchison JG; Reddy KR; Afdhal N;
    Gastroenterology; 2015 Sep; 149(3):649-59. PubMed ID: 25985734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study.
    Osinusi A; Kohli A; Marti MM; Nelson A; Zhang X; Meissner EG; Silk R; Townsend K; Pang PS; Subramanian GM; McHutchison JG; Fauci AS; Masur H; Kottilil S
    Ann Intern Med; 2014 Nov; 161(9):634-8. PubMed ID: 25364884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial.
    Andrieux-Meyer I; Tan SS; Thanprasertsuk S; Salvadori N; Menétrey C; Simon F; Cressey TR; Said HRHM; Hassan MRA; Omar H; Tee HP; Chan WK; Kumar S; Thongsawat S; Thetket K; Avihingsanon A; Khemnark S; Yerly S; Ngo-Giang-Huong N; Siva S; Swanson A; Goyal V; Bompart F; Pécoul B; Murad S
    Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):448-458. PubMed ID: 33865507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study.
    Wei L; Xie Q; Hou JL; Tang H; Ning Q; Cheng J; Nan Y; Zhang L; Li J; Jiang J; McNabb B; Zhang F; Camus G; Mo H; Osinusi A; Brainard DM; Gong G; Mou Z; Wu S; Wang G; Hu P; Gao Y; Jia J; Duan Z
    Hepatol Int; 2018 Mar; 12(2):126-132. PubMed ID: 29637511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.